Search Results - "Dahlberg, Suzanne E"

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions by Oxnard, Geoffrey R, Lo, Peter C, Nishino, Mizuki, Dahlberg, Suzanne E, Lindeman, Neal I, Butaney, Mohit, Jackman, David M, Johnson, Bruce E, Jänne, Pasi A

“…Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is…”
Get more information

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer by Sacher, Adrian G, Dahlberg, Suzanne E, Heng, Jennifer, Mach, Stacy, Jänne, Pasi A, Oxnard, Geoffrey R

“…Non-small-cell lung cancer (NSCLC) diagnosed in young patients is rare, and the genomics and clinical characteristics of this disease are poorly understood. In…”
Get more information

Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 by VROOMAN, Lynda M, STEVENSON, Kristen E, LAVERDIERE, Caroline, LIPSHULTZ, Steven E, MICHON, Bruno, SCHORIN, Marshall, RELLING, Mary V, COHEN, Harvey J, NEUBERG, Donna S, SALLAN, Stephen E, SILVERMAN, Lewis B, SUPKO, Jeffrey G, O'BRIEN, Jane, DAHLBERG, Suzanne E, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, KELLY, Kara M, KUTOK, Jeffery L

“…We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents…”
Get full text

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial by Neal, Joel W, Dr, Dahlberg, Suzanne E, PhD, Wakelee, Heather A, MD, Aisner, Seena C, Prof, Bowden, Michaela, PhD, Huang, Ying, MD, Carbone, David P, Prof, Gerstner, Gregory J, MD, Lerner, Rachel E, MD, Rubin, Jerome L, MD, Owonikoko, Taofeek K, MD, Stella, Philip J, MD, Steen, Preston D, MD, Khalid, Ahmed Ali, MD, Ramalingam, Suresh S, Prof

“…Summary Background Erlotinib is approved for the treatment of all patients with advanced non-small-cell lung cancer (NSCLC), but is most active in the…”
Get full text

Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas by Russell‐Goldman, Eleanor, Kravets, Sasha, Dahlberg, Suzanne E., Sholl, Lynette M., Vivero, Marina

“…BACKGROUND Programmed cell death protein 1 inhibitors increasingly are being used to treat patients with advanced lung carcinomas. Programmed death‐ligand 1…”
Get full text

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer by Govindan, Ramaswamy, Mandrekar, Sumithra J, Gerber, David E, Oxnard, Geoffrey R, Dahlberg, Suzanne E, Chaft, Jamie, Malik, Shakun, Mooney, Margaret, Abrams, Jeffrey S, Jänne, Pasi A, Gandara, David R, Ramalingam, Suresh S, Vokes, Everett E

“…The treatment of patients with metastatic non-small cell lung cancer (NSCLC) is slowly evolving from empirical cytotoxic chemotherapy to personalized treatment…”
Get full text

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes by LIPSHULTZ, Steven E, MILLER, Tracie L, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, LAVERDIERE, Caroline, MICHON, Bruno, SCHORIN, Marshall A, SALLAN, Stephen E, SCULLY, Rebecca E, LIPSITZ, Stuart R, RIFAI, Nader, SILVERMAN, Lewis B, COLAN, Steven D, NEUBERG, Donna S, DAHLBERG, Suzanne E, HENKEL, Jacqueline M

“…Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help…”
Get full text

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 by DAHLBERG, Suzanne E, SANDLER, Alan B, BRAHMER, Julie R, SCHILLER, Joan H, JOHNSON, David H

“…PURPOSE Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) with demonstrated efficacy in combination with carboplatin…”
Get full text

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer by Redig, Amanda J, Capelletti, Marzia, Dahlberg, Suzanne E, Sholl, Lynette M, Mach, Stacy, Fontes, Caitlin, Shi, Yunling, Chalasani, Poornima, Jänne, Pasi A

“…NF1 is a tumor suppressor that negatively regulates Ras signaling. NF1 mutations occur in lung cancer, but their clinical significance is unknown. We evaluated…”
Get full text

Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease by Lo, Ruby C., MD, Bensley, Rodney P., MD, Dahlberg, Suzanne E., PhD, Matyal, Robina, MD, Hamdan, Allen D., MD, Wyers, Mark, MD, Chaikof, Elliot L., MD, PhD, Schermerhorn, Marc L., MD

“…Objective Prior studies have suggested treatment and outcome disparities between men and women for lower extremity peripheral arterial disease after surgical…”
Get full text

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data by Mauguen, Audrey, MSc, Pignon, Jean-Pierre, Dr, Burdett, Sarah, MSc, Domerg, Caroline, MSc, Fisher, David, MSc, Paulus, Rebecca, BS, Mandrekar, Samithra J, PhD, Belani, Chandra P, Prof, Shepherd, Frances A, MD, Eisen, Tim, Prof, Pang, Herbert, PhD, Collette, Laurence, PhD, Sause, William T, MD, Dahlberg, Suzanne E, PhD, Crawford, Jeffrey, Prof, O'Brien, Mary, MD, Schild, Steven E, MD, Parmar, Mahesh, DPhil, Tierney, Jayne F, PhD, Pechoux, Cécile Le, MD, Michiels, Stefan, PhD

“…Summary Background The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and…”
Get full text

Outcomes following infrapopliteal angioplasty for critical limb ischemia by Lo, Ruby C., MD, Darling, Jeremy, BA, Bensley, Rodney P., MD, Giles, Kristina A., MD, Dahlberg, Suzanne E., PhD, Hamdan, Allen D., MD, Wyers, Mark, MD, Schermerhorn, Marc L., MD

“…Objective Infrapopliteal angioplasty (percutaneous transluminal angioplasty [PTA]) is routinely used to treat critical limb ischemia (CLI) despite limited data…”
Get full text

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599 by RAMALINGAM, Suresh S, DAHLBERG, Suzanne E, LANGER, Corey J, GRAY, Robert, BELANI, Chandra P, BRAHMER, Julie R, SANDLER, Alan B, SCHILLER, Joan H, JOHNSON, David H

“…Fit elderly patients with advanced non-small-cell lung cancer (NSCLC) benefit from platinum-based, two-drug chemotherapy. Bevacizumab (B) in combination with…”
Get full text

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer by Ivanova, Elena, Kuraguchi, Mari, Xu, Man, Portell, Andrew J, Taus, Luke, Diala, Irmina, Lalani, Alshad S, Choi, Jihyun, Chambers, Emily S, Li, Shuai, Liu, Shengwu, Chen, Ting, Barbie, Thanh U, Oxnard, Geoffrey R, Haworth, Jacob J, Wong, Kwok-Kin, Dahlberg, Suzanne E, Aref, Amir A, Barbie, David A, Bahcall, Magda, Paweletz, Cloud P, Jänne, Pasi A

“…Evaluating drug responses using primary patient-derived cells represents a potentially rapid and efficient approach to screening for new treatment approaches…”
Get full text

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer by Ricciuti, Biagio, Kravets, Sasha, Dahlberg, Suzanne E, Umeton, Renato, Albayrak, Adem, Subegdjo, Safiya J, Johnson, Bruce E, Nishino, Mizuki, Sholl, Lynette M, Awad, Mark M

“…Clinically-available biomarkers to identify the fraction of patients with small cell lung cancer (SCLC) who respond to immune-checkpoint inhibitors (ICIs) are…”
Get full text

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 by Horn, Leora, Dahlberg, Suzanne E, Sandler, Alan B, Dowlati, Afshin, Moore, Dennis F, Murren, John R, Schiller, Joan H

“…To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC)…”
Get full text

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 by Morgensztern, Daniel, Campo, Meghan J, Dahlberg, Suzanne E, Doebele, Robert C, Garon, Edward, Gerber, David E, Goldberg, Sarah B, Hammerman, Peter S, Heist, Rebecca S, Hensing, Thomas, Horn, Leora, Ramalingam, Suresh S, Rudin, Charles M, Salgia, Ravi, Sequist, Lecia V, Shaw, Alice T, Simon, George R, Somaiah, Neeta, Spigel, David R, Wrangle, John, Johnson, David, Herbst, Roy S, Bunn, Paul, Govindan, Ramaswamy

“…There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A…”
Get more information

Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study by TIEN HOANG, DAHLBERG, Suzanne E, SCHILLER, Joan H, MEHTA, Minesh P, FITZGERALD, Thomas J, BELINSKY, Steven A, JOHNSON, David H

“…The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with…”
Get full text

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development by Lampson, Benjamin L., Nishino, Mizuki, Dahlberg, Suzanne E., Paul, Danie, Santos, Abigail A., Jänne, Pasi A., Oxnard, Geoffrey R.

“…BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor…”
Get full text

Volumetric Tumor Response and Progression in EGFR -mutant NSCLC Patients Treated with Erlotinib or Gefitinib by Nishino, Mizuki, MD, Dahlberg, Suzanne E., PhD, Fulton, Linnea E, Digumarthy, Subba R., MD, Hatabu, Hiroto, MD, PhD, Johnson, Bruce E., MD, Sequist, Lecia V., MD

“…Rationale and Objectives The aims of this study were to investigate the association between 8-week tumor volume decrease and survival in an independent cohort…”
Get full text